233 related articles for article (PubMed ID: 9001979)
1. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.
Reed JA; McNutt NS; Bogdany JK; Albino AP
J Cutan Pathol; 1996 Dec; 23(6):495-505. PubMed ID: 9001979
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression.
Reed JA; McNutt NS; Albino AP
Am J Pathol; 1994 Feb; 144(2):329-36. PubMed ID: 8311116
[TBL] [Abstract][Full Text] [Related]
3. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions.
Khare VK; Albino AP; Reed JA
J Cutan Pathol; 1998 Jan; 25(1):2-10. PubMed ID: 9508337
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor.
Tóth-Jakatics R; Jimi S; Takebayashi S; Kawamoto N
Hum Pathol; 2000 Aug; 31(8):955-60. PubMed ID: 10987256
[TBL] [Abstract][Full Text] [Related]
5. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
6. The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi.
Lu S; Slominski A; Yang SE; Sheehan C; Ross J; Carlson JA
J Cutan Pathol; 2010 Apr; 37 Suppl 1(Suppl 1):26-40. PubMed ID: 20482673
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
8. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
Krengel S; Grotelüschen F; Bartsch S; Tronnier M
J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
[TBL] [Abstract][Full Text] [Related]
9. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study.
Dyduch G; Okoń K; Pescarini E
Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-1 in the tumor microenvironment correlates with melanoma invasion.
Chiriboga L; Meehan S; Osman I; Glick M; de la Cruz G; Howell BS; Friedman-Jiménez G; Schneider RJ; Jamal S
Melanoma Res; 2016 Jun; 26(3):236-44. PubMed ID: 26825037
[TBL] [Abstract][Full Text] [Related]
11. Mast cells in cutaneous tumors: innocent bystander or maestro conductor?
Biswas A; Richards JE; Massaro J; Mahalingam M
Int J Dermatol; 2014 Jul; 53(7):806-11. PubMed ID: 23621615
[TBL] [Abstract][Full Text] [Related]
12. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness.
Kunz M; Hartmann A; Flory E; Toksoy A; Koczan D; Thiesen HJ; Mukaida N; Neumann M; Rapp UR; Bröcker EB; Gillitzer R
Am J Pathol; 1999 Sep; 155(3):753-63. PubMed ID: 10487833
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D
J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556
[TBL] [Abstract][Full Text] [Related]
15. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
16. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
17. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Schmid P; Itin P; Rufli T
Carcinogenesis; 1995 Jul; 16(7):1499-503. PubMed ID: 7614683
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization.
Sparrow LE; Heenan PJ
Australas J Dermatol; 1999 Feb; 40(1):19-24. PubMed ID: 10098284
[TBL] [Abstract][Full Text] [Related]
19. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
20. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]